Business Context and Reporting Period
Company: Merit Medical Systems, Inc. (MMSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Segment Reporting: Effective Q1 2026, the company reports as a single operating segment with two product categories: Foundational and Therapeutic.
Leadership: Martha G. Aronson serves as Chief Executive Officer and Chief Operating Decision Maker.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net Sales | $418,843 | $382,462 | $800,720 | $737,813 |
| Gross Profit | $215,166 | $184,487 | $399,963 | $356,507 |
| Gross Margin % | 51.4% | 48.2% | 50.0% | 48.3% |
| Operating Income | $60,403 | $46,880 | $104,560 | $87,913 |
| Net Income | $38,803 | $32,581 | $79,798 | $62,728 |
| Diluted EPS | $0.65 | $0.54 | $1.33 | $1.03 |
| Operating Cash Flow (6mo) | $109,957 | $123,879 | ||
| Cash & Equivalents (End of Period) | ||||
| Long-Term Debt | $736,258 (Convertible Notes) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9.5% ($36.4M) for the quarter and 8.5% ($62.9M) for the six months compared to the prior year. Growth was driven by both domestic (11.0% Q/Q) and international (7.3% Q/Q) regions.
- Margin Expansion: Gross margin improved to 51.4% (Q/Q) and 50.0% (6mo) due to favorable product mix and approximately $6.9M in refunds of previously paid IEEPA tariffs recognized in cost of sales.
- Acquisitions: Completed the acquisition of View Point Medical, Inc. on April 1, 2026, for a total consideration of approximately $137.3M (net of cash). This added the OneMark Detection Imaging System to the portfolio.
- Divestitures: Sold the DualCap product line to Health Line International Corporation in February 2026 for $28M, resulting in a pre-tax book gain of $12.5M.
- Operating Expenses: SG&A expenses increased 14.3% for the quarter, driven by labor costs, commissions, and $5.6M in acquisition-related costs for View Point.
- Other Income/Expense: Included a one-time charge of $5.1M for additional interest on Convertible Notes due to delayed removal of restrictive legends, partially offset by the $12.5M gain on the DualCap divestiture.
Guidance, Outlook, and Risks
- Capital Expenditures: Management anticipates spending approximately $80M to $100M in 2026 for property and equipment, including a new distribution facility in South Jordan, Utah.
- Liquidity: As of June 30, 2026, the company held $450.9M in cash, cash equivalents, and restricted cash. Available borrowing capacity under the Amended Fourth A&R Credit Agreement is approximately $697M.
- Tax Outlook: The effective tax rate for the six months ended June 30, 2026, was 23.9%. The company is monitoring OECD Pillar 2 global minimum tax rules but does not currently anticipate a material impact due to safe harbor rules.
- Risks:
- Geopolitical: Ongoing conflict involving the U.S., Israel, and Iran poses risks to supply chains, energy prices, and global trade.
- Debt Covenants: The company must maintain specific leverage and interest coverage ratios under its credit agreement and convertible note indenture.
- Integration: Risks associated with integrating View Point Medical and realizing anticipated synergies.
- Tariffs: Uncertainty remains regarding the recovery of remaining tariff amounts for which the company is not the importer of record.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and financial impact of integrating View Point Medical's OneMark system into existing operations.
- Tariff Refunds: Confirm the status of the $6.9M IEEPA tariff refund and the likelihood of recovering additional amounts for non-importer-of-record items.
- Convertible Notes: Monitor the status of restrictive legends on the $747.5M Convertible Notes to avoid future "Additional Interest" charges.
- Inventory Levels: Review the $43.6M cash outflow for inventory during the six-month period to ensure it aligns with demand forecasts and does not signal obsolescence risks.
- Divestiture Transition: Assess the impact of the DualCap sale on future revenue streams and the terms of the transition services agreement with Health Line.